docetaxel + prednisone + zoledronic acid

This is a combination regimen consisting of three drugs: docetaxel, prednisone, and zoledronic acid. Docetaxel is a taxane-class chemotherapeutic agent that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells. Prednisone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties; it also helps reduce some side effects of chemotherapy and may have direct antitumor activity in prostate cancer. Zoledronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption, reducing skeletal-related events in patients with bone metastases from solid tumors such as prostate cancer. This combination has been shown to be safe and effective for the management of hormone-refractory (castration-resistant) prostate cancer with bone metastases[1][2][3]. Zoledronic acid may provide synergistic benefit by reducing complications from bone metastases[3].

Brand names

Dexamethasone Intensol

Other names

prednisolone (for prednisone, as sometimes used interchangeably in clinical protocols)zoledronate (alternative name for zoledronic acid)